Walker, Janek S. http://orcid.org/0000-0002-2049-1527
Hing, Zachary A.
Sher, Steven
Cronin, James
Williams, Katie
Harrington, Bonnie
Skinner, Jordan N.
Cempre, Casey B.
Gregory, Charles T.
Pan, Alexander
Yano, Max
Beaver, Larry P.
Walker, Brandi R.
Labanowska, Jadwiga M.
Heerema, Nyla A.
Mrózek, Krzysztof
Woyach, Jennifer A. http://orcid.org/0000-0002-3403-9144
Ruppert, Amy S. http://orcid.org/0000-0001-9612-6473
Lehman, Amy
Ozer, Hatice Gulcin
Coppola, Vincenzo http://orcid.org/0000-0001-6163-1779
Yan, Pearlly http://orcid.org/0000-0003-1965-4920
Byrd, John C. http://orcid.org/0000-0001-9830-0711
Blachly, James S. http://orcid.org/0000-0002-4275-5562
Lapalombella, Rosa http://orcid.org/0000-0001-6916-9400
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (NIGMS T32 GM068412, NCATS TL1 TR002735)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA214046)
Article History
Received: 25 February 2021
Accepted: 21 September 2021
First Online: 3 November 2021
Competing interests
: J.S.B. has performed consulting for AbbVie, AstraZeneca, Innate, and KITE Pharma. J.C.B. performed consulting for AstraZeneca, Takada, Novartis, Pharmacyclics, Syndex, and Trillium. J.C.B. chairs the scientific board of Vincera Pharmaceuticals and has significant equity in this company. All other authors declare no competing interests.